Literature DB >> 1399940

Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds.

J C Barrière1, D H Bouanchaud, J M Paris, O Rolin, N V Harris, C Smith.   

Abstract

Pristinamycin displays unique antibacterial properties due to the synergy between its two components, pristinamycin I and pristinamycin II. Because this antibiotic is not water-soluble, its administration is restricted to the oral route, and its therapeutic potential is thereby limited. Novel water-soluble derivatives of the naturally-occurring antibiotic pristinamycin were obtained by modifications of its two major components. The modifications included regioselective and stereoselective substitution alpha to the carbonyl group in the 4-oxo-pipecolic acid residue of pristinamycin IA (PIA) and stereoselective conjugate addition to the double bond of the dehydroproline ring in pristinamycin IIA (PIIA). We report here the in-vitro and in-vivo activities of some representative water-soluble derivatives of pristinamycin IA and pristinamycin IIA against Staphylococcus aureus reference strains, sensitive or resistant to methicillin and/or macrolides.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399940     DOI: 10.1093/jac/30.suppl_a.1

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci.

Authors:  M C Struwig; P L Botha; L J Chalkley
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

2.  In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections.

Authors:  R Garcia; I Raad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

Review 3.  Streptogramins. A unique class of antibiotics.

Authors:  J C Pechère
Journal:  Drugs       Date:  1996       Impact factor: 9.546

4.  Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies.

Authors:  G A Pankuch; C Lichtenberger; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

Review 5.  Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci.

Authors:  M G Cormican; R N Jones
Journal:  Drugs       Date:  1996       Impact factor: 9.546

6.  In-vitro activity of synercid and related drugs against Streptococcus oralis isolated from septicaemia and endocarditis cases.

Authors:  A M Rafay
Journal:  J Sci Res Med Sci       Date:  2000-01

7.  Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.

Authors:  M J Rybak; H H Houlihan; R C Mercier; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

8.  MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

9.  Pharmacokinetics and suction blister fluid penetration of a semisynthetic injectable streptogramin RP 59500 (RP 57669/ RP 54476).

Authors:  E Bernard; M Bensoussan; F Bensoussan; S Etienne; I Cazenave; E Carsenti-Etesse; Y Le Roux; G Montay; P Dellamonica
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-09       Impact factor: 3.267

10.  In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

Authors:  L A Collins; G J Malanoski; G M Eliopoulos; C B Wennersten; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.